Mariachiara Dipasquale
Overview
Explore the profile of Mariachiara Dipasquale including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
40
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Veccia A, Dipasquale M, Lorenzi M, Monteverdi S, Kinspergher S, Zambotti E, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002263
The treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients was dramatically revolutionized by the introduction of EGFR tyrosine kinase inhibitors in clinical practice, both in advanced...
2.
Veccia A, Dipasquale M, Kinspergher S, Caffo O
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594826
Introduction: In recent years, several inflammation-related factors and nutritional parameters have been evaluated to develop prognostic scores as potential biomarkers in non-small-cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors...
3.
Ferro A, Campora M, Caldara A, De Lisi D, Lorenzi M, Monteverdi S, et al.
J Clin Med
. 2024 Jun;
13(12).
PMID: 38930141
Estrogen receptor (ER)-positive breast cancer (BC) is the most common BC subtype. Endocrine therapy (ET) targeting ER signaling still remains the mainstay treatment option for hormone receptor (HR)-positive BC either...
4.
Ferro A, Generali D, Caffo O, Caldara A, De Lisi D, Dipasquale M, et al.
Semin Oncol
. 2023 Sep;
50(3-5):90-101.
PMID: 37673696
Endocrine therapy (ET) targeting estrogen receptor (ER) signaling is still the mainstay treatment option for early or advanced ER-positive breast cancer (BC) and may involve suppressing estrogen production by means...
5.
Veccia A, Dipasquale M, Kinspergher S, Monteverdi S, Girlando S, Barbareschi M, et al.
Target Oncol
. 2022 Dec;
18(1):129-138.
PMID: 36482151
Background: KRAS is the most frequently mutated gene in non-small cell lung cancer (NSCLC), however conflicting data are available on its role as a biomarker. Objective: The aim of our...
6.
Veccia A, Kostine M, Tison A, Dipasquale M, Kinspergher S, Prokop L, et al.
Joint Bone Spine
. 2022 May;
89(4):105403.
PMID: 35508288
Objectives: We aimed to analyze rheumatic immune-related (ir) and nonimmune-related adverse events (AEs) due to immune-checkpoint inhibitors (ICIs) targeting programmed cell death-1 or its ligand PD-(L)1 in lung cancer patients...
7.
Veccia A, Sforza V, Vattemi E, Inno A, Kinspergher S, Dipasquale M, et al.
Immunotherapy
. 2021 Jun;
13(13):1093-1103.
PMID: 34190578
To investigate the role of pretreatment lung immune prognostic index (LIPI) as biomarker in PD-L1 ≥50% non-small-cell lung cancer patients receiving pembrolizumab. We retrospectively identified 117 patients, divided into three...
8.
Berti A, Bortolotti R, Dipasquale M, Kinspergher S, Prokop L, Grandi G, et al.
Crit Rev Oncol Hematol
. 2021 May;
162:103351.
PMID: 33989769
Introduction: The introduction in clinical practice of the immune checkpoint inhibitors (ICIs) radically changed the treatment algorithm of lung cancers. To characterize the toxicity of ICIs (atezolizumab, durvalumab, nivolumab, pembrolizumab)...
9.
Veccia A, Kinspergher S, Dipasquale M, Caffo O
Future Oncol
. 2021 Jan;
17(5):597-609.
PMID: 33401981
The brain is one of the most frequent sites of metastases in lung cancer patients, whose prognosis is related to the histological, biomolecular and clinical features of the disease. Over...
10.
Veccia A, Girlando S, Dipasquale M, Kinspergher S, Barbareschi M, Caffo O
J BUON
. 2020 Jun;
25(2):848-854.
PMID: 32521877
Purpose: The EGFR (Epidermal Growth Factor Receptor) mutations may predict sensitivity and resistance to EGFR-TKIs (Tyrosine Kinases Inhibitors) in metastatic lung adenocarcinoma. The detection of these mutations is usually performed...